GPT-Rosalind
OpenAI's first domain-specific reasoning model for biology and drug discovery, launched April 16 2026 as a US-only research preview with a 0.751 BixBench score.
Biotech
OpenAI Releases GPT-Rosalind for Drug Discovery
OpenAI launched GPT-Rosalind on April 16, a frontier reasoning model for drug discovery that outranked human experts on RNA prediction and competes directly with Google DeepMind's AlphaFold.
Novo Nordisk Bets Its Drug Pipeline on OpenAI
Novo Nordisk signs a sweeping AI partnership with OpenAI covering drug discovery, manufacturing, and supply chain - but the governance details are thin.
Anthropic Pays $400M for AI Drug Discovery Startup
Anthropic acquires Coefficient Bio, an eight-month-old stealth startup with fewer than ten employees, in a $400M all-stock deal to push into pharmaceutical AI.
AI-Designed mRNA Vaccine Shrinks Dog's Cancer Tumor
Sydney entrepreneur Paul Conyngham used ChatGPT and AlphaFold to design a personalized mRNA vaccine that shrank his rescue dog's mast cell tumor by 75% - the first AI-designed cancer vaccine for a dog.
Evo 2 Is the Largest Open-Source Biology AI Ever Built
Arc Institute and NVIDIA release Evo 2, a 40B-parameter open-source AI trained on 9.3 trillion nucleotides from every domain of life, with full weights, code, and training data.
Isomorphic Labs Unveils IsoDDE, an 'AlphaFold 4' That Scientists Cannot See Inside
Google DeepMind's drug discovery spin-off releases a proprietary AI engine that doubles AlphaFold 3's accuracy but breaks with the open-science tradition that made its predecessor a Nobel Prize winner.
